In this expert interview, Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses donor selection for allogeneic stem cell transplantation in secondary acute myeloid leukemia (AML) patients who are in their first complete remission. He explains that while sibling donors still yield the best overall survival and lowest transplant-related mortality, haploidentical transplants using post-transplant cyclophosphamide have shown comparable outcomes to de novo AML cases, offering a promising alternative when sibling or unrelated donors aren’t available